About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Managed Access Programs for SEG101, Crizanlizumab | Clinical Trials | Clareo Health

Back to clinical trial search

AVAILABLENCT03720626

Managed Access Programs for SEG101, Crizanlizumab

The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab

Lead sponsor: Novartis Pharmaceuticals•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

MAP requests are initiated by a licensed physician. https// www.novart is.com/healthcare-professionals/managed-access-programs

CONTACT

+41613241111 novartis.email@novartis.com

Novartis Pharmaceuticals

CONTACT

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

CSEG101A2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CSEG101A2001M to provide access to Crizanlizumab for sickle cell disease patients with history of vaso-occlusive crisis

Age

12 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•An independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.

Exclusion Criteria

•There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
•The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
•Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
•Managed Access provision is allowed per local laws/regulations.

Related studies

RECRUITINGPhase 3

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

NCT06818266 · Sickle Cell Disease, Acute Chest Syndrome

Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease

NCT06477289 · Sickle Cell Disease

RECRUITINGPhase 3

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268 · Sickle Cell Disease

ATHNdataset Registry

NCT06820515 · Hemophilia, Thrombosis, and more

Functional Ovarian Reserve in Sickle Cell Disease

NCT07392216 · Sickle Cell Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 14, 2026Terms

Trial snapshot

StatusAVAILABLE

Phase—

Enrollment—

Start date—

Last updatedApr 14, 2026

Condition

Sickle Cell Disease

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 14, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions